Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease

Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial

(2013) Douglas G Day et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication

(2012) Sudipta Ghosh et al.   CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Risk Factors to Develop Ocular Surface Disease in Treated Glaucoma or Ocular Hypertension Patients

(2012) Gemma Caterina Maria Rossi et al.   EUROPEAN JOURNAL OF OPHTHALMOLOGY

Economic impact of primary open-angle glaucoma in Australia

(2011) Mohamed Dirani et al.   CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Prevalence of Ocular Surface Complaints in Patients With Glaucoma Using Topical Intraocular Pressure-Lowering Medications

(2010) Robert D Fechtner et al.   CORNEA

Prevalence of Dry Eye Disease Among US Men

(2009) Debra A. Schaumberg   ARCHIVES OF OPHTHALMOLOGY

Prevalence of Ocular Surface Disease in Glaucoma Patients

(2009) Eamon W. Leung et al.   JOURNAL OF GLAUCOMA

Ocular Surface Tolerability of Prostaglandin Analogs in Patients with Glaucoma or Ocular Hypertension

(2009) Jess T. Whitson et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma

(2008) Christophe Baudouin   ACTA OPHTHALMOLOGICA